Results 131 to 140 of about 36,401 (249)

Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 2023-2033, June 2025.
Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Shodai Kawanami   +11 more
wiley   +1 more source

The efficacy and safety of sodium‐glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure

open access: yesESC Heart Failure, Volume 12, Issue 3, Page 2087-2097, June 2025.
Abstract Aims Sodium‐glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) have demonstrated effectiveness in reducing cardiovascular death and heart failure hospitalization (HFH). However, the efficacy and safety of SGLT2 inhibitors in elderly patients with poor general status, such as very low bodyweight or low nutritional status, who are not included ...
Kenji Nakano   +15 more
wiley   +1 more source

Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation

open access: yesClinical Transplantation, Volume 39, Issue 6, June 2025.
ABSTRACT Introduction Targets for continuous glucose monitoring (CGM) are well established for type 1 and type 2 diabetes. In total pancreatectomy with islet autotransplantation (TPIAT), stricter glycemic targets are needed to avoid metabolic stress on transplanted islets, but no guidelines exist for CGM targets.
Zaynab Somani   +6 more
wiley   +1 more source

Euglycemic Diabetic Ketoacidosis in a Pregnant Patient on Insulin Pump Therapy

open access: yesAACE Clinical Case Reports
Background/Objective: Diabetic ketoacidosis is a common endocrine emergency. A subset of patients present with euglycemic diabetic ketoacidosis, which may be diagnosed late due to its rarity and relatively lower blood glucose levels.
Hesham Yasin, MD   +3 more
doaj  

Home - About - Disclaimer - Privacy